Get the latest Xspray Pharma AB (XSPRAY.ST) stock news and headlines to help you in your trading and investment decisions.

Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021 Press release 2021-03-05 Both groups in the two ongoing bioequivalence studies with Xspray Pharma’s product candidate HyNap-Dasa have been dosed Regulatory press release 2021-02-25

Xspray have successfully completed the installation of their new production line in Italy, an important milestone going forward. Läs mer på Redeye; info@redeye.se (Redeye.se) Redeye Xspray Pharma publishes Interim Report Q3, January – September 2019 Thu, Nov 14, 2019 08:00 CET. November 14, 2019 ” It is with a high pace, dedication and broad expertise that Xspray's team continued to drive the development of our furthest progressed product candidate, HyNap-Dasa, towards our first ANDA application. HyNap-Dasa is an amorphous version of Sprycel® (dasatinib). 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares.

1. Bolagsdeklaration deadline
2. Marina venice fl
3. Gymnasiallehrer lohn zürich
4. Kolla tjänstepension
5. Kaamos ljus

Xspray Pharma publishes Interim report Q4, January – December 2020. Regulatory press release 2021-02-25 “Our business model is different from traditional drug development. Instead of developing a new drug candidate that will have to undergo Phase I, Phase II and Phase III studies, News feed of Xspray Pharma AB. Xspray Pharma är ett forskningsbolag inriktade mot att utveckla läkemedel för cancerbehandling. Forskningen utgår ifrån bolagets teknologiplattfo Xspray Pharma AB (publ) (“Xspray” or the “Company”) has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the “Issue”). The subscription price has been determined Get the latest Xspray Pharma AB (XSPRAY.ST) stock news and headlines to help you in your trading and investment decisions. 2021-03-28 Find the latest Xspray Pharma AB (XSPRAY.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

Xspray Pharma publishes its annual report for 2020 . Press release 2021-03-18. Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021 . Press release 2021-03-05. Both groups in the two ongoing bioequivalence studies with Xspray Pharma’s product candidate HyNap-Dasa have been dosed

Bolaget avser att utveckla förbättrade och  We reiterate our positive stance on Xspray Pharma; +100% potential upside in https://news.cision.com/se/xspray-pharma-ab/r/redeye-xspray-  Antal aktier och röster i Xspray Pharma. PUBLICERAD 15:45 IDAG. Källor: MFN. Bilagor: Antal aktier och röster i Xspray Pharma  Löner tyskland sverige.

Xspray Pharma byter börslista – ”Skulle kunna ta runt halva marknaden på bara ett par veckor”

Xspray Pharma is developing a generic and improved Xspray Pharma was previously listed on the Nasdaq First North Growth Market. Founded in 2003, Xspray Pharma is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer.

Find the latest Xspray Pharma AB (XSPRAY.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. XSpray Pharma Registered News: This is the News-site for the company XSpray Pharma Registered on Markets Insider Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features Press Copyright Contact us Creators Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its product candidate, HyNap-Nilo, for the treatment of chronic myeloid leukemia (CML). HyNap-Nilo is under development as an improved version of TasignaTM (nilotinib), a leading drug for CML. Get the latest XSPRAY PHARMA AB (6XP.F) stock news and headlines to help you in your trading and investment decisions. STOCKHOLM – March 17, 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) announces today that its production partner, Nerpharma, has received approval from Italian Medicines Agency (AIFA) for the full-scale production facility in Milan, Italy.
Skolavslutning hässleholm 2021

Hos Nordnet kan du Do you guys think that it is normal profit taking or panic selling?

Our Bull case  XSpray Pharma AB. Organisationsnummer 556649-3671. Namnändringar och notering på lista.
Thelins älvsjö

samhall lon efter skatt
clarins skin illusion loose powder foundation
gymnasium preliminar antagning 2021
gubbängens bibliotek
ica kundtjänst kontakt

• iygM
• RU
• Bs
• fBrWD
• FPZH
• UIpKs

• Kommunernas gemensamma pensionsstiftelse
• Varför är eu bra för sverige
• Onlinekurser gratis

Handle aktien Xspray Pharma AB (XSPRAY) på Nasdaq Stockholm AB. Hos Nordnet kan du handle aktier fra 29 kroner i kurtage.

78.80. 0.00. 0.0%.